학술논문

A clinicopathologic study of malignancy in VCP-associated multisystem proteinopathy
Document Type
article
Source
Orphanet Journal of Rare Diseases. 17(1)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Aging
Rare Diseases
Prevention
Cancer
Genetics
Clinical Research
Aetiology
2.1 Biological and endogenous factors
Adenosine Triphosphatases
Cell Cycle Proteins
Humans
Male
Mutation
Myositis
Inclusion Body
Neoplasms
Retrospective Studies
Valosin Containing Protein
VCP
Myopathy
Paget disease of bone
Frontotemporal dementia
IBMPFD
Multisystem proteinopathy
Peripheral nerve sheath tumor
Anaplastic pleomorphic xanthoastrocytoma
Thymoma
Other Medical and Health Sciences
Genetics & Heredity
Clinical sciences
Language
Abstract
BackgroundValosin containing protein (VCP) is an important protein with many vital functions mostly related to the ubiquitin-proteasome system that provides protein quality control. VCP-associated inclusion body myopathy with Paget disease of bone and frontotemporal dementia, also termed VCP disease and multisystem proteinopathy (MSP 1), is an autosomal dominant disorder caused by monoallelic variants in the VCP gene on human chromosome 9. VCP has also been strongly involved in cancer, with over-activity of VCP found in several cancers such as prostate, pancreatic, endometrial, esophageal cancers and osteosarcoma. Since MSP1 is caused by gain of function variants in the VCP gene, we hypothesized our patients would show increased risk for developing malignancies. We describe cases of 3 rare malignancies and 4 common cancers from a retrospective dataset.ResultsUpon surveying 106 families with confirmed VCP variants, we found a higher rate of rare tumors including malignant peripheral nerve sheath tumor, anaplastic pleomorphic xanthoastrocytoma and thymoma. Some of these subjects developed cancer before displaying other classic VCP disease manifestations. We also present cases of common cancers; however, we did not find an increased rate compared to the general population. This could be related to the early mortality associated with this disease, since most patients die in their 50-60 s due to respiratory failure or cardiomyopathy which is earlier than the age at which most cancers appear.ConclusionThis is the first study that expands the phenotype of VCP disease to potentially include rare cancers and highlights the importance of further investigation of the role of VCP in cancer development. The results of this study in VCP disease patients suggest that patients may be at an increased risk for rare tumors. A larger study will determine if patients with VCP disease develop cancer at a higher rate than the general population. If that is the case, they should be followed up more frequently and screened for recurrence and metastasis of their cancer.